MedTrace Logo

Determination of Blood Loss After CS

NCT04549012 · Status: UNKNOWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 130

Last updated 2020-09-16

No results posted yet for this study

Summary

Comparing betweeen tranexamic acid plus oxytocin and oxytocin alone in their efficacy in reducing blood loss following CS

Conditions

  • Effect of Drug

Interventions

DRUG

Tranexamic acid

comparison between effect of oxytocin alone and tranexamic acid and oxytocin in reducing blood loss after CS

DRUG

Oxytocin

Oxytocin

Sponsors & Collaborators

  • Ain Shams University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-09-30
Primary Completion
2021-09-30
Completion
2021-10-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04549012 on ClinicalTrials.gov